Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co To Break New Ground With Female-Led Organon Unit

Former Chair And CEO Of Humacyte, Carrie Cox To Serve As Chair

Executive Summary

The planned spin-off of Merck & Co’s Organon unit, with annual sales of $6.5bn including from biosimilars, is nearing completion, with the originator filing documentation with the SEC and unveiling a progressive female-majority board of directors for the new company.

You may also be interested in...



Organon Continues Building Women’s Health Portfolio With Forendo Buyout

The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.

Organon Completes Spin-Out From Merck With Five Biosimilars

With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.

What’s Next? Five Things To Look Out For In June

In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel